Investigation Launched into Eli Lilly’s Operations in China
John Moolenaar, the chairman of the Chinese Communist Party’s House Select Committee, has initiated an inquiry into Eli Lilly’s clinical trial practices in China. The committee is focusing on research conducted at hospitals linked to the Chinese military, particularly in Xinjiang.
In a letter obtained recently, Moolenaar’s committee, representing the Republican Party from Michigan, requested extensive details about Eli Lilly’s operations in China. This includes inquiries about how the company maintains ethical standards and protects sensitive biotech and intellectual property, especially regarding research tied to veterans at military-affiliated hospitals in Xinjiang, a region where the Chinese government faces accusations of human rights violations against Uyghurs and other ethnic minorities.
As of now, records indicate that Lilly has sponsored or collaborated on over 220 clinical studies in China since 2003, with at least 11 trials specifically in the Xinjiang area and around 16 involving military medical centers. Some of these studies are still ongoing.
This investigation signifies a growing concern among Congress regarding the expanding relationship between U.S. pharmaceutical firms and China. Lawmakers express apprehension that clinical research happening in military hospitals and Xinjiang could present risks to national security, infringe on intellectual property rights, and exacerbate human rights issues.
Moolenaar clarified that there is currently “no evidence that Mr. Lilly has engaged in any illegal activity or wrongdoing.” However, the committee is cautious about the implications of conducting trials in locations where access to biotech research data might benefit China’s military operations.
Competitive Landscape in Biotechnology
Moolenaar also pointed out that the U.S. is in a competitive race with China in biotechnology. He noted that this sector has become crucial for national security and economic competitiveness, with implications for the protection of American health data. He mentioned that China’s latest five-year plan prioritizes biotechnology and emphasizes the increased use of AI in this field.
China has quickly become one of the least expensive and most efficient places for early-stage human drug trials, a transformation aided by regulatory reforms and financial incentives. While this speed holds a certain appeal for global drug development, it simultaneously raises ethical and data security concerns.
Expanding Presence and Partnerships in China
As Eli Lilly continues to grow its footprint in China, the company announced an investment of around $3 billion to enhance local manufacturing and supply operations, increasing its total investment in the region to nearly $6 billion. Moreover, Lilly has forged substantial partnerships with Chinese biotech firms, including a notable collaboration worth up to $8.8 billion with Innovent Biologics and a deal of about $3 billion with Hisco Pharmaceutical Group.
Moolenaar’s letter brought attention to questions about the adequacy of participant protections in China’s clinical trial framework. Reports indicate that many trial participants may misunderstand the experimental nature of studies or mistakenly believe that treatments have already been proven effective, which raises significant concerns regarding informed consent.
Additionally, the letter pointed out irregularities with trials conducted in Xinjiang, referencing claims from various human rights organizations and U.N. reports that indicate forced medical testing and other abuses targeting Uyghurs. Moolenaar suggested that such circumstances could lead to more scrutiny over the voluntariness of participants in that region.
The committee is also wary that research conducted at hospitals affiliated with the People’s Liberation Army might enable proprietary data, gathered during sensitive biotech studies, to end up benefiting China’s military biotechnology initiatives.
Moolenaar has set a deadline of July 17 for Lilly to submit documents detailing its due diligence, inspections of clinical trial locations, and safeguards protecting sensitive data and intellectual property. In response, a Lilly spokesperson mentioned, “We received a letter from the House Select Committee on China and are carefully reviewing it.”
